Dedicated to creating life-changing medicines for people with
limited or no options.
Home Science

Research and Development

We focus on creating a thoughtful development strategy for every molecule and treatment we pursue, whether we partner with other leading organizations to study a new therapy or leverage our own research to usher a medicine from early stage development to patients in the marketplace.

We continue to invest in our growing research and development capabilities. We actively explore revolutionary drug options ranging from small molecule advancements to biologics, and novel compounds within neuroscience and oncology. This dynamic approach has allowed us to shepherd new medicines to market — from late-stage discovery through clinical development and regulatory approval.

Pipeline

PRE-CLINICAL
Undisclosed targets
Neuroscience
CombiPlex
Exploratory activities

JZP-341 (Long-acting Erwinia asparaginase)2
ALL/other hematological malignancies

Recombinant Pegaspargase1
Hematological malignancies

Pan-RAF Inhibitor program
Raf & Ras mutant tumors
Undisclosed targets
Ras/Raf/MAP kinase pathway2
Exosome targets (NRAS, STAT3 and 3 others)2
Hematological malignancies/solid tumors

Defibrotide
Exploratory activities

PHASE 1
JZP-324
Oxybate extended-release formulation
CPX-351
Low Intensity Dosing for higher risk MDS3

CPX-351 + other approved therapies
  • R/R AML or HMA Failure MDS3
  • First-line, fit AML (Phase 1b)
  • Low Intensity Therapy for first-line, unfit AML (Phase 1b)

PHASE 2
JZP-3854
Essential tremor (Phase 2b)

JZP-1504
PTSD
CPX-351
  • HR-MDS (EMSCO)5
  • Newly diagnosed older adults with HR-AML4,5
CPX-351 + venetoclax
de novo or R/R AML3

PHASE 3
CPX-351
  • AML or HR-MDS >60 yrs (AML18)5
  • AML or HR-MDS >18 yrs (AML19)5
  • Newly diagnosed adults with standard- and HR-AML (AMLSG)5
  • Newly diagnosed <22 yrs with AML (COG)5
REGULATORY
JZP-258
Idiopathic hypersomnia

JZP-458 (recombinant Erwinia asparaginase)
ALL/LBL (pivotal Phase 2/3)

Neuroscience
Hematology/Oncology
1Opt-in opportunity
2Partnered collaboration
3Jazz & MD Anderson Cancer Center collaboration study
4Planned
5Cooperative group study
6Exclusive U.S. license
*PF-04457845

Through Jazz’s patented CombiPlex® platform, Jazz is evaluating oncology combinations to support identification of clinical product candidate(s) and is leading a collaborative approach with partners to research and develop new therapies.